Alectinib is a second-generation anaplastic lymphoma kinase (ALK; CD246) inhibitor, used in patients with NSCLC with the echinoderm microtubule-associated protein-like 4–anaplastic lymphoma kinase (EML4–ALK) gene rearrangement [1]. Here, EML4 is linked to non-small cell lung carcinoma.